Column: This is how the Danish Medicines Council should strengthen its application process

Roche and Novartis have been behind almost 10 percent of all application submissions to the Danish Medicines Council since 2017. In a column, representatives from both firms point out three problems and make concrete proposals for how to improve the council’s work.
by Darine Ghanem, General Manager for Roche Pharma Denmark & Iceland, and Peter Drøidal, Country Manager for Denmark & Nordic Head Market Access at Novartis, translated by daniel pedersen

In 2021, the Danish Medicines Council processed 50 new drug applications. Unfortunately, the established allotted case processing time of 84 days was exceeded with every application. This is the fifth year in a row that case processing got behind schedule, according to the council’s latest year-in-review.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading